EYAL DAVIDOVITS
Profile
Related Companies
Titles
Company Name
Related People
EXECUTIVE OFFICER, DIRECTOR
EXECUTIVE OFFICER, DIRECTOR
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D
BIOTECHNOLOGY
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835]
DECLINE TO DISCLOSE
Equity
2023-08-11
D
BIOTECHNOLOGY
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835]
DECLINE TO DISCLOSE
Equity
2022-11-04
D
BIOTECHNOLOGY
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835]
DECLINE TO DISCLOSE
Equity
2021-10-13
D
BIOTECHNOLOGY
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835]
DECLINE TO DISCLOSE
Equity
2020-12-24
D
BIOTECHNOLOGY
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835]
DECLINE TO DISCLOSE
Equity
2020-12-03
D
BIOTECHNOLOGY
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835]
DECLINE TO DISCLOSE
Equity
2019-10-25
D
BIOTECHNOLOGY
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835]
DECLINE TO DISCLOSE
Equity
2019-04-12
D
BIOTECHNOLOGY
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835]
DECLINE TO DISCLOSE
Equity
2019-03-04
D
BIOTECHNOLOGY
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835]
DECLINE TO DISCLOSE
Equity
2017-12-28

